Analytical and Bioanalytical Chemistry

Supplementary Information

An integrated strategy of MS-network- based offline 2DLC-QTOF-MS/MS coupled with UHPLC-QTRAP[®]-MS/MS for the characterization and quantification of the non-polysaccharides in Sijunzi Decoction

Bangjian Dong¹, Chongsheng Peng¹, Ping Ma, Xiaobo Li*

School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, Shanghai, 200240, China

Index of Contents

Fig. S1 The first dimensional separation: HPLC-DAD chromatograms of NPSs in SJZD (A) at 210 nm; (B) at 254 nm.

Fig. S2 Comparison of the separation selectivity of four RP columns for SJZD components using CH3CN-0.1% water-containing formic acid for as the mobile phase (data recorded on an Agilent UHPLC-QTOF-MS instrument. Sample A was used for optimization. a is liquiritin; b is liquiritin apioside).

Fig. S3 Base peak intensity chromatograms (BPCs) in negative and positive ion mode of Fractions 1–5.

Fig. S4 Tandem mass spectra of six potential new compounds A25 (A), A52(B), C73 (C), C94 (D), C154 (E), and C210 (F).

Fig. S5 Representative MRM chromatograms of 19 analytes from Sample B1 (A) and Sample B2 (B).

Table S1 UHPLC-QTRAP[®]-MS/MS parameters for the quantification.



Fig. S1 The first dimensional separation: HPLC-DAD chromatograms of NPSs in SJZD (A) at 210 nm; (B) at 254 nm.



Fig. S2 Comparison of the separation selectivity of four RP columns for SJZD components using CH₃CN-0.1% water-containing formic acid for as the mobile phase (data was recorded on an Agilent UHPLC-QTOF-MS instrument. Sample A was used for optimization. a is liquiritin; b is liquiritin apioside).





Fig. S3 Base peak intensity chromatograms (BPCs) in positive and negative ion mode of Fractions 1–5.





Fig. S4 Tandem mass spectra of six potential new compounds A25 (A), A52(B), C73 (C), C94 (D), C154 (E), and C210 (F).



Fig. S5 Representative MRM chromatograms of 19 analytes from Sample B1 (A) and Sample B2 (B).

NO.	Compound	Formula	RT	Quantifier	Qualifier	CE ^a	DP	СХР
			(min)	(m/z)	(<i>m</i> / <i>z</i>)	(eV)	(eV)	(eV)
1	Liquiritin apioside	$C_{26}H_{30}O_{13}$	3.59	549.2→255.1	549.2→135.0	-50	-100	-15
2	Liquiritin	$C_{21}H_{22}O_9$	3.63	417.1→255.1	417.1→135.0	-28	-100	-15
3	Isoliquiritin apioside	$C_{26}H_{30}O_{13}$	5.35	549.2→255.1	549.2→135.0	-50	-100	-15
4	Isoliquiritin	$C_{21}H_{22}O_9$	5.60	417.1→255.1	417.1→135.0	-28	-100	-15
5	Ononin	$C_{22}H_{22}O_9$	5.75	475.1→267.1	475.1→252.0	-30	-100	-15
6	Liquiritigenin	$C_{15}H_{12}O_4$	6.15	255.1→135.0	255.1→119.2	-30	-100	-15
7	Ginsenoside Re	$C_{48}H_{82}O_{18}$	6.17	991.6→945.5	991.6→799.5	-30	-100	-15
8	Ginsenoside Rg1	$C_{42}H_{72}O_{14} \\$	6.20	845.5→799.5	845.5→637.6	-30	-100	-15
9	Ginsenoside Rf	$C_{42}H_{72}O_{14}$	8.42	845.5→799.5	845.5→637.6	-30	-100	-15
10	Isoliquiritigenin	$C_{15}H_{12}O_4$	9.10	255.1→135.0	255.1→119.2	-30	-100	-15
11	Ginsenoside Rb1	$C_{54}H_{92}O_{23}$	9.12	1153.6→1107.6	1153.6→945.5	-30	-100	-15
12	Ginsenoside Rg2	$C_{42}H_{72}O_{13}$	9.22	829.5→783.5	829.5→637.6	-30	-100	-15
13	Ginsenoside Rc	$C_{53}H_{90}O_{22}$	9.46	1123.6→1077.6	1123.6→945.5	-30	-100	-15
14	Formononetin	$C_{16}H_{12}O_4$	9.48	267.1→252.0	267.1→223.0	-30	-100	-15
15	Ginsenoside Rb2	$C_{53}H_{90}O_{22}$	9.76	1123.6→1077.6	1123.6→945.5	-30	-100	-15
16	Glycyrrhizic acid	$C_{42}H_{62}O_{16}$	10.43	821.4→351.1	821.4→193.1	-58	-100	-15
17	Ginsenoside Rd	$C_{48}H_{82}O_{18}$	10.51	991.6→945.5	991.6→783.5	-30	-100	-15
18	Ginsenoside Rg3	$C_{42}H_{72}O_{13}$	13.75	829.5→783.5	829.5→621.5	-30	-100	-15
19	Ginsenoside Rk1	$C_{42}H_{70}O_{12}$	16.26	811.5→765.5	811.5→161.3	-30	-100	-15

Table S1 UHPLC/QTRAP[®]-MS/MS parameters for the quantification.

^a the CE values was applied for quantifier ions